UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Survey by SFRO, SNRO and AFPPE about the evolution of the radiation therapist profession in France

Cancer radiothérapie, 2023-12, Vol.27 (8), p.712-717

2023

Volltextzugriff (PDF)

Radiation therapists shortage in France: Organizational consequences and difficulties in deploying new missions and/or tasks delegation

Cancer radiothérapie, 2023-09, Vol.27 (6-7), p.577-582

2023

Volltextzugriff (PDF)

The Living Concrete Experiment: Cultivation of Photosynthetically Active Microalgal on Concrete Finish Blocks

Sustainability, 2024-03, Vol.16 (5), p.2147

2024

Volltextzugriff (PDF)

Recommendations for stereotactic body radiation therapy for spine and non-spine bone metastases. A GETUG (French society of urological radiation oncolgists) consensus using a national two-round modified Delphi survey

Clinical and translational radiation oncology, 2022-11, Vol.37, p.33-40

2022

Volltextzugriff (PDF)

Indications and outlooks of radiohormonal therapy of high-risk prostate cancers

Cancer radiothérapie, 2020-04, Vol.24 (2), p.143

2020

Volltextzugriff (PDF)

Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group

Cancer radiothérapie, 2020-12, Vol.24 (8), p.892-897

2020

Volltextzugriff (PDF)

Stereotactic body radiation therapy for spine and non-spine bone metastases. GETUG (french society of urological radiation oncologists) recommendations using a national two-round modified Delphi survey

Clinical and translational radiation oncology, 2022-11, Vol.37, p.33-40

2022

Volltextzugriff (PDF)

Randomized Phase 3 Trial of Dose Escalation (80 vs 70 Gy) in High-Risk Prostate Cancers Combined With Long-term Androgen Deprivation: GETUG-AFU 18 Trial, Acute and 1-Year Toxicities

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (3), p.S44-S45

2015

Volltextzugriff (PDF)

Strategies and solutions to green concrete construction material

E3S web of conferences, 2024, Vol.546, p.1005

2024

Volltextzugriff (PDF)

Salvage therapy for vagal nerve stimulator infection; Literature review and report of a delayed recurrence

Clinical neurology and neurosurgery, 2021-01, Vol.200, p.106333-106333, Article 106333

2021

Volltextzugriff (PDF)

Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy

European urology open science (Online), 2020-07, Vol.19, p.e1398-e1399

2020

Volltextzugriff (PDF)

Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma

Journal of neuro-oncology, 2010, Vol.96 (2), p.277-285

2010

Volltextzugriff (PDF)

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

British journal of cancer, 2019-12, Vol.121 (12), p.1001-1008

2019

Volltextzugriff (PDF)

Risk factors for anxiety and depression among pregnant women during the COVID‐19 pandemic: Results of a web‐based multinational cross‐sectional study

International journal of gynecology and obstetrics, 2023-01, Vol.160 (1), p.167-186

2023

Volltextzugriff (PDF)

Multivariate Assessment of Tumor Angiogenesis as a Prognostic Factor for Survival in Patients with Oligodendroglioma and Anaplastic Oligodendroglioma

International journal of radiation oncology, biology, physics, 2008, Vol.72 (1), p.S216-S216

2008

Volltextzugriff (PDF)

1595MO Phenotypic and genomic characterization of de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase III trial

Annals of oncology, 2024-09, Vol.35, p.S962-S962

2024

Volltextzugriff (PDF)

OC-0434 Long -term results of OLIGOPELVIS, a Phase II Trial of pelvic RT in Oligorecurrent Prostate Cancer

Radiotherapy and oncology, 2023-05, Vol.182, p.S334-S335

2023

Volltextzugriff (PDF)

1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial

Annals of oncology, 2023-10, Vol.34, p.S978-S979

2023

Volltextzugriff (PDF)

OC-0831 Results of ARTIX phase III study: adaptive radiotherapy versus standard IMRT in head and neck cancer

Radiotherapy and oncology, 2022-05, Vol.170, p.S749-S750

2022

Volltextzugriff (PDF)

673P Cabozantinib-nivolumab (CN) vs. nivolumab-cabozantinib (NC) in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) following one prior VEGFR tyrosine kinase inhibitor (TKI): The CABIR multicentric matching-adjusted study

Annals of oncology, 2021-09, Vol.32, p.S696-S697

2021

Volltextzugriff (PDF)

603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial

Annals of oncology, 2021-09, Vol.32, p.S646-S647

2021

Volltextzugriff (PDF)

OC-0433 GETUG-AFU 22 phase II randomized trial : final results on clinical outcomes with immediate SRT

Radiotherapy and oncology, 2023-05, Vol.182, p.S334-S334

2023

Volltextzugriff (PDF)

1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial

Annals of oncology, 2022-09, Vol.33, p.S1164-S1165

2022

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(145)

Publikationsform

Sprache

Englisch
(134)
Französisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(55)
Humans
(42)
Oncology
(28)
Male
(27)
Aged
(17)
Female
(17)
Life Sciences
(17)
Middle Aged
(17)
Prostate Cancer
(13)
Adult
(11)
Prognosis
(11)
Radiology, Nuclear Medicine & Medical Imaging
(10)
Cancer
(9)
Chemotherapy
(9)
Prospective Studies
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Aged, 80 And Over
(7)
Biological And Medical Sciences
(7)
Medical Sciences
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Survey by SFRO, SNRO and AFPPE about the evolution of the radiation therapist profession in France

Radiation therapists shortage in France: Organizational consequences and difficulties in deploying new missions and/or tasks delegation

The Living Concrete Experiment: Cultivation of Photosynthetically Active Microalgal on Concrete Finish Blocks

Recommendations for stereotactic body radiation therapy for spine and non-spine bone metastases. A GETUG (French society of urological radiation oncolgists) consensus using a national two-round modified Delphi survey

Indications and outlooks of radiohormonal therapy of high-risk prostate cancers

Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group

Stereotactic body radiation therapy for spine and non-spine bone metastases. GETUG (french society of urological radiation oncologists) recommendations using a national two-round modified Delphi survey

Randomized Phase 3 Trial of Dose Escalation (80 vs 70 Gy) in High-Risk Prostate Cancers Combined With Long-term Androgen Deprivation: GETUG-AFU 18 Trial, Acute and 1-Year Toxicities

Strategies and solutions to green concrete construction material

Salvage therapy for vagal nerve stimulator infection; Literature review and report of a delayed recurrence

Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy

Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

Risk factors for anxiety and depression among pregnant women during the COVID‐19 pandemic: Results of a web‐based multinational cross‐sectional study

Multivariate Assessment of Tumor Angiogenesis as a Prognostic Factor for Survival in Patients with Oligodendroglioma and Anaplastic Oligodendroglioma

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA

1595MO Phenotypic and genomic characterization of de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase III trial

OC-0434 Long -term results of OLIGOPELVIS, a Phase II Trial of pelvic RT in Oligorecurrent Prostate Cancer

1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial

OC-0831 Results of ARTIX phase III study: adaptive radiotherapy versus standard IMRT in head and neck cancer

673P Cabozantinib-nivolumab (CN) vs. nivolumab-cabozantinib (NC) in patients (pts) with metastatic clear cell renal cell carcinoma (mRCC) following one prior VEGFR tyrosine kinase inhibitor (TKI): The CABIR multicentric matching-adjusted study

603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial

OC-0433 GETUG-AFU 22 phase II randomized trial : final results on clinical outcomes with immediate SRT

1363MO Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial

Suchergebnisse filtern